Tryp Therapeutics Stock Price To Book
Tryp Therapeutics fundamentals help investors to digest information that contributes to Tryp Therapeutics' financial success or failures. It also enables traders to predict the movement of Tryp OTC Stock. The fundamental analysis module provides a way to measure Tryp Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tryp Therapeutics otc stock.
Tryp |
Tryp Therapeutics OTC Stock Price To Book Analysis
Tryp Therapeutics' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Tryp Therapeutics Price To Book | 2.50 X |
Most of Tryp Therapeutics' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tryp Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
CompetitionBased on the latest financial disclosure, Tryp Therapeutics has a Price To Book of 2.499 times. This is 90.27% lower than that of the Healthcare sector and 58.63% lower than that of the Biotechnology industry. The price to book for all United States stocks is 73.72% higher than that of the company.
Tryp Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tryp Therapeutics' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Tryp Therapeutics could also be used in its relative valuation, which is a method of valuing Tryp Therapeutics by comparing valuation metrics of similar companies.Tryp Therapeutics is currently under evaluation in price to book category among its peers.
Tryp Fundamentals
| Return On Equity | -9.22 | |||
| Return On Asset | -2.05 | |||
| Current Valuation | 4.17 M | |||
| Shares Outstanding | 96.42 M | |||
| Shares Owned By Insiders | 47.24 % | |||
| Shares Owned By Institutions | 0.04 % | |||
| Price To Book | 2.50 X | |||
| EBITDA | (7.36 M) | |||
| Net Income | (7.49 M) | |||
| Cash And Equivalents | 2.85 M | |||
| Cash Per Share | 0.03 X | |||
| Current Ratio | 6.14 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (5.81 M) | |||
| Earnings Per Share | (0.13) X | |||
| Beta | -1.29 | |||
| Market Capitalization | 6.56 M | |||
| Total Asset | 2.34 M | |||
| Z Score | -9.9 | |||
| Net Asset | 2.34 M |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Tryp OTC Stock
If you are still planning to invest in Tryp Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tryp Therapeutics' history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |